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Eight bioactive drug compounds (abamectin, amoxicillin, dexamethasone, dexamethasone valerate,
ketoprofen, melatonin, oestradiol 17b, and oestradiol benzoate) were combined via melt extrusion and
disc pressing processes with a polycaprolactone (PCL) matrix and were then evaluated and compared
via membrane diffusion and Hanson dissolution studies. This investigation was to determine the
potential of this matrix to act as a controlled release drug delivery vehicle for a number of drugs not
previously combined with PCL in a melt extrusion mix. The inclusion of the progesterone/PCL system,
for which the drug release behaviour has been well studied before was intended for comparison with
the PCL systems incorporating drugs that have received little research attention in the past. Initial
studies centred on an evaluation of the permeation ability of the bioactive drugs dissolved in aqueous
cyclodextrin solutions through a poly(e-caprolactone) (PCL) membrane using Valia-Chien side-by-side
cells. Permeation rates were mostly low and found to range from 0 to 122 mg h1 with only ketoprofen,
melatonin, and progesterone displaying rates exceeding 20 mg h1. Hanson dissolution release proﬁles
in aqueous alcohol were subsequently measured for the 9 melt extruded PCL/drug combinations and
led to Hanson release rates of 0–556 mg cm2 h0.5 with dexamethasone, dexamethasone valerate,
ketoprofen, melatonin, and progesterone giving values exceeding 100 mg cm2 h0.5. A number of
drugs such as the dexamethasones probably performed better than they did in the permeability rate
measurements because of the less polar aqueous alcoholic solvent used. In searching for useful
correlations between the drug physicochemical properties and release rate, only a moderate correlation
(R2¼0.5675) between Hanson dissolution release rate and permeation rate was found. This suggests
that the release rate and the permeation are both controlled by the rate of drug diffusion through the
PCL with release rate involving an additional dissolution process (of the drug) before permeation occurs
accounting for the moderate correlation. In general, of the eight drugs considered, it was clear that the
oestradiol-based drugs, abamectin, and amoxicillin were generally not suited to drug delivery via PCL
under the conditions used. However, ketoprofen was found to be very suitable as a drug candidate for
melt extrusion with PCL with dexamethasone valerate, dexamethasone, and melatonin also showing
potential as candidates though to a much lesser extent.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
Physical approaches to drug delivery involve the incorporation
of the drug with some form of synthetic polymer. Examplesll rights reserved.
rdyne),include melt-extruded drug-bearing ﬁlms, capsules, or particles
(inert or bio-erodible) that can be applied to the skin, taken orally,
implanted subcutaneously, injected, or inserted into various body
cavities [1–5]. The kinetics of release for the system becomes a
property of the polymer matrix (physical attributes) [6] and drug
used (physicochemical properties) [7]. Physical approaches of
drug delivery are good for sustained drug action throughout the
body or for maintaining high levels within a particular body
compartment (example, intravaginal). The principle behind phy-
sical drug delivery systems is a sustained drug level through
balancing the pharmacokinetic processes and the drug-release
S.J. Gardyne et al. / Results in Pharma Sciences 1 (2011) 80–87 81characteristics of the polymer used [8,9]. It is in this category that
a great deal of work has been carried out to investigate the
possibility of oestrus control (examples, progesterone and oes-
tradiol) via an intravaginal drug delivery system in both humans
and livestock [10].
The need for developing the intravaginal drug delivery route
has been driven by the inability of existing routes to achieve the
clinical requirements desired by the animal industry (veterinary
and farming). From its infancy in the 1960s, that saw the ﬁrst
trials using polyurethane sponges for delivering progesterone, has
evolved an industry whose potential is far from reached. Animal,
veterinary, and plastic engineering scientists [10] initiated an
explosion in design concepts with little input from formulation
scientists, the outcomes of which were some inherent pharma-
ceutical problems (drug load, excessive vaginal discharge). Too
rapid development of these delivery systems led to commercial
availability within two years of conception, another contributing
factor to the inherent problems [10]. Only recently has a more
rigorous pharmaceutical science approach been applied to inves-
tigate the viability of the intravaginal route and already many
innovations have resulted especially in the ﬁeld of oestrus control
(examples include the active delivery device, C-shaped plasthyd
device, CIDR, Cue-mate, intelligent breeding device, INVAS, PCL,
PRID, Rajamehendran rubber tubing, Ring, Rod, and Sponges)
[11–14]. Many of these devices are expensive, difﬁcult to manu-
facture, or persist in the environment, the noticeable exception
being poly(e-caprolactone) (PCL), a simple, relatively inexpensive
and biodegradable polymer [15]. The successful melt-extrusion of
progesterone and PCL for the oestrus control of cattle has shown
that sustained drug delivery from this simple matrix device is
commercially viable. The manufacture of these devices also is
relatively cost effective with the added beneﬁt that the biode-
gradation products have been shown to have a low impact on the
environment [14].
The viability of incorporating bioactive drug compounds into a
melt-extruded matrix system like PCL polymer can be achieved
without costly animal trials through some relatively inexpensive
in vitro methods. Side-by-side cell permeation trials can indicate
any innate potential for the drug to diffuse through the polymer
before incorporation through, for instance, melt-extrusion with
the polymer can be considered. Dissolution experiments with the
melt-extruded drug/polymer matrix may then be carried out to
show the relative release rates of the drug from the polymer
indicating the potential therapeutic levels possible. SEM analysis
of the morphology of a matrix system can also highlight features
as a result of the combining of the drug and polymer.
Currently the principal commercial applications of intravaginal
drug delivery are in providing end users (veterinary professionals,
farmers) a convenient means of oestrus control in production
animals (dairy, meat, and equine) [10]. Little is known about theTable 1
The bioactive class and melting pointsa of the drug candidates considered for melt ext
Bioactive compound
Abamectin
Amoxicillin ((6R)-6-[a–D-(4-hydroxyphenyl)glycylamino]penicillanic acid)
Dexamethasone (Pregna-1,4-diene-3,20-dione, 9-ﬂuoro-11,17,21-trihydroxy-16-meth
Dexamethasone valerate (Pregna-1,4-diene-3,20-dione,9-ﬂuoro-11b,17,21-trihydroxy
Ketoprofen (2-[3–benzoylphenyl] propionic acid)
Melatonin (N-acetyl-5-methoxytryptamine)
Oestradiol 17-b (estra-1,3,5(10)-triene-3,17b-diol)
Oestradiol benzoate (estra-1,3,5(10)-triene-3,17b-diol 3-benzoate)
Progesterone (pregn-4-ene-3,20-dione)
a Values are obtained from Refs. [36–39].
b Decomposes on melting.use of this pathway to administer other drugs such as antibiotics
or anthelmintics. Presently, a successful PCL device [14] is avail-
able for the controlled delivery of progesterone regulating the
oestrus cycle of cattle and PCL as a vehicle has been studied before
(along with other melt extrudable matrices) in the delivery of
various drugs [16], but there is sparse drug delivery-associated
literature available for PCL melt extruded with other potentially
useful bioactive drug compounds such as abamectin, amoxicillin,
dexamethasone, dexamethasone valerate, ketoprofen, melatonin,
oestradiol 17-b, and oestradiol benzoate The aim of this research,
therefore, was to investigate the melt extrusion of these particular
drugs with a PCL platform for the controlled release delivery of
these bioactive drug compounds. It was also the aim of this paper
to correlate release rate from (and permeation rate through) PCL
with the physicochemical properties of the drugs tested to gain
insights into drug delivery behaviour. The progesterone/PCL sys-
tem was included in this study for comparison as this has been
studied extensively before [14]. The intended target receptors for
devices containing such drugs could be, among others, the vaginal
mucosa of cattle and this has dictated the release medium used for
the Hanson dissolution work carried out in this study (namely
aqueous alcohol mixtures) which are intended to simulate the
amphiphilic nature of the vaginal and other biological membranes
with respect to dissolution of drug from the drug-containing PCL
matrices.2. Materials and methods
2.1. Materials
Table 1 lists the drugs considered in this study together with
their medical application and melting points.
Abamectin (94.3%) was supplied by Ancare NZ Ltd, New
Zealand, with amoxicillin (99.2%) being supplied by Biochemie,
Austria. Ketoprofen (100.1%) was supplied by Bidachem, Italy
while melatonin (99.0%) was supplied by Flamma, Italy. Oestra-
diol 17-b (99.4%) and oestradiol benzoate (100.0%) were supplied
by Gedeon Richter Ltd, Budapest, and progesterone (99.5%) was
supplied by DEC manufacturing (NZ) Ltd. Dexamethasone (99.0%)
and dexamethasone valerate (101.0%) were supplied by Crystal
Pharma, Spain and were regarded as two differently behaving
drugs in this study because of the presence of the valerate
functionality in the latter drug. Results from these two dexa-
methasone drugs are hence reported as separate substances. PCL
powder (Capa 6806, Batch #003046/2C) was sourced from Solvay
caprolactones, UK. Hydroxy propyl beta cyclodextrin (HPbCD)
was from Sigma-Aldrich, Australia. All chemicals and reagents
were used as received from the various suppliers. All water used
was doubly distilled on a glass still.rusion into PCL.
Bioactive class mp (1C)
Anthelmintic 155–157
Anti-biotic 194
yl-, (11b,16a)- ) Hormone 255 Db
-16a-methyl-, 17-valerate) Hormone 192
Anti-inﬂammatory 94
Hormone 117
Hormone 173
Hormone 191–198
Hormone 126–130
Table 2
UV lmax (nm) and extinction coefﬁcient (e) values identiﬁed for the eight selected
drugs of interest that were used in the assaying of the drugs in addition to
progesterone.
Drug kmax (nm) e (mL cm
1 lg1)
Abamectin 244 0.0792
Amoxicillin 228 0.0239
Dexamethasone 242 0.0326
Dexamethasone valerate 242 0.0301
Ketoprofen 258 0.0580
Melatonin 223 0.1036
Oestradiol 17-b 217 0.0255
Oestradiol benzoate 232 0.0439
Progesterone 244 0.0474
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A 1.0 mg mL1 stock solution of each drug (0.0500 g of drug in
a 50 mL volumetric ﬂask) in SDA (Specially Denatured Alcohol)
was prepared. Standards of 20 mg mL1 (1.0 mL aliquot of stock
solution made up to 50 mL in a volumetric ﬂask) in HPbCD/PBS
(pH 5.0 phosphate buffer solution (PBS) containing 9.2 g sodium
dihydrogen orthophosphate 1-hydrate with 0.0946 g di-sodium
hydrogen orthophosphate and 5% w/v hydroxypropyl-b-cyclodex-
trin (to aid dissolution) in 1.0 L of distilled water) were used to
analyse for each drug’s UV lmax value by performing a wavelength
scan from 200 to 300 nm (Biochrom Libra S12 UV spectrophoto-
meter) and identifying the peak of maximum absorbance. The
lmax values (Table 2) obtained for the nine drug compounds of
interest all occurred in the 220–250 nm region [17,18]. All nine
drug compounds (which includes progesterone) gave linear Beer’s
law plots which were used to measure drug concentrations for
the permeation and Hanson dissolution studies (see later).2.3. PCL membrane manufacture for drug permeation studies
The PCL membranes were manufactured by heating PCL
polymer spheres (3–6 mm diameter) at 125 1C in a bench-top
oven for 30 min on two aluminium plates, with removal from the
oven and pressing together (using a vice) with feeler gauges to set
the ﬁnal thickness to 150710 mm. For the purposes of standar-
dising their manufacture in terms of the rate of solidiﬁcation, the
membranes were allowed to cool for 30 min with the assistance
of an electric fan while they were pressed together.Table 3
Hanson dissolution standard method operating conditions.
Condition Setting
Stirring element Paddle
Release mediaa 15% v/v SDA:water (de-ionised), placed in the
ultrasonic bath for 40 min to remove air
Media volume 500 mL
Temperature 37.070.5 1C
Ionic adjustment None
pH adjustment None
Rotation speed 10072% rpm
Sampling times 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 h
Device A square shaped (28 by 2871 mm, E0.240 mm
thick) 10% w/w drug/PCL tab with a surface area
of 16007100 mm2
UV wavelength 244 nm
Sampling 1.0 mL manually taken
a 15% v/v SDA:water was judged to be the optimal level of aqueous alcohol
that gave minimal UV interference from dissolved PCL polymer itself.2.4. Side-by-side diffusion cells for drug permeation studies
A Valia-Chien side-by-side diffusion cell [19] was connected
to a circulating waterbath (supplying the heat jackets) set at
3772 1C with a PCL membrane (150710 mm) placed between
the donor and receptor cells. The donor cell (3.4 mL volume)
contained the saturated drug in a HPbCD/PBS solution with the
receptor cell (3.4 mL volume) initially containing only the HPbCD/
PBS solution. Both cells were mixed with magnetic stirring ﬂeas
to ensure homogeneity. Samples (1.0 mL) were taken from the
receptor cell at times ranging from 0.5 h to 24 h (depending on
the permeation rate initially observed for each drug) and analysed
by UV spectrophotometry, via an appropriate calibration curve, at
the drug’s lmax value. A fresh 1.0 mL solution of HPbCD/PBS was
added to the receptor cell after each sample had been removed to
maintain a constant volume of 3.4 mL (the dilution effect and
volume changes were factored in when calculating total receptor
cell mg permeated).2.5. Manufacture of the melt extruded drug/PCL devices for Hanson
dissolution studies
Manufacture of the drug/PCL devices (for the nine drug
candidates selected) was achieved by mixing PCL powder with
drug at a loading of ca.10% w/w, then heating to 80 1C in a syringe
(100 cc volume, 8 mm nozzle diameter) for 2 h, and ﬁnally
extruding the melted mix from the syringe. The mixture was then
cooled and chipped to 10 mm lengths. In this sense the material
used to form the discs for later study can be considered as being
formed from a process which approaches a melt extrusion process.
This chipped material from the initial extrusion process containing
the PCL and the drug was then remelted and subsequently
fabricated into a disc by placing it on two aluminium plates in
an oven at 80 1C for 1 h, removing and pressing (using a vice)
together at room temperature to cool for 30 min with the
assistance of an electric fan (feeler gauges on the plates deter-
mined the ﬁnal thickness to be ca. 0.250 mm). The discs were then
cut into 28 mm by 28 mm (71 mm) square shapes to give a ﬁnal
total surface area of 16007100 mm2 (when both sides and the
edges are factored in to the surface area calculation). In forming
these discs, the remelting of the chipped material allowed homo-
genisation of the drug and PCL prior to pressing into discs.
2.6. Hanson dissolution testing of the extruded PCL/drug matrices
Preliminary Hanson dissolution release rate assessment for
the progesterone/PCL devices was adapted from the principles
deﬁned in USP 23 NF18, January 1995, section 724, page 1793
[20] (see Table 3). The ‘‘Apparatus 2’’ procedure was used with the
following modiﬁcations. A release media volume of 500 mL of
15% v/v SDA:water (degassed) at 3770.5 1C with no adjustment
for pH or ionic strength was placed into the Hanson dissolution
ﬂasks. This choice of release medium was dictated by the
intended target receptors of such devices namely the bovine
vaginal membrane for which aqueous alcohol mixes are a good
simulation of the membrane. The devices remained completely
submerged in the release media (they sank on introduction), were
unattached, and free to move about once the paddles began to
rotate (10072% rpm set 25 mm above the bottom of the test
ﬂask). This ensured that the total surface area of the devices was
exposed throughout the release test. The time intervals for
manual sample collection (1.0 mL) and immediate analysis
(to prevent evaporation) were 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 9.0,
15.0, and 24.0 h after starting. To monitor drug release from the
matrices, the concentration of the drug (e.g. progesterone) was
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amount of drug (e.g. progesterone) released per unit area of
device versus the square-root-of-time was performed to give a
linear relationship, the slope of which equated to an in vitro drug
release rate.0
0.1
0.2
0 2 4 6 8 10
Time (hours)
Fig. 2. A typical ﬂux (J, (mg cm2 min1)) proﬁle (melatonin) associated with the
permeation of a drug through the PCL membrane.
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Fig. 3. Permeation rates (mg h1) for the eight selected drugs of interest in
addition to progesterone.3. Results and discussion
3.1. Data analysis from the work involving side-by-side diffusion
cells for drug permeation studies
From the Valia-Chien side by side diffusion cell work, the
plotting of cumulative permeation (mg) of drug into the receptor
cell versus time (hours) at steady state was conﬁrmed to produce
a linear relationship (Fig. 1). The slope of this graph can be related
to the permeation rate (mg h1) of the drug through the PCL
membrane. Using the measured surface area (A) of the membrane
and the value of the saturated concentration (Cd) of the drug in
the donor cell containing HPbCD/PBS, the permeability coefﬁcient
(P) can be calculated in accordance with
P¼ Slope
ACd
ð1Þ
In the permeability experiments performed using the Valia-
Chien side-by-side diffusion cells, the principal factors known to
determine P were the permeation rate and the Cd of the drug in
question as surface area, A of the membrane remains constant
throughout. At the start of the plot, an artefact known as the lag
time (tL) (see Fig. 1), occurs due to the physical restraints of the
initial diffusion of solvent and drug to permeate into the ‘‘dry’’
membrane resulting in a non-linear response. According to the
literature [21] the tL can be extrapolated by taking the intercept of
the steady-state line (ignoring the non-steady-state at the start of
the experiment) on the time axis which gives a value of approxi-
mately 1.5 h in the example shown in Fig. 1.
Calculations of the ﬂux values (J) to assess the variability
associated with permeation over time for drug candidates were
performed using Fick’s ﬁrst law (Eq. (2)) [22]
J¼ Q
At
ð2Þ
where Q is the quantity of drug crossing the membrane (mg),
A, the total exposed membrane area (cm2), and t the time of
exposure (minutes). Analysis of the ﬂux (J) throughout the
experiments done with the Valia-Chien cells clearly showed the
initial permeation rate changes over time until a constant value
was achieved (Fig. 2).0
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Fig. 1. A typical permeation proﬁle for melatonin obtained using the Valia-Chien
side-by-side diffusion cells (total mg melatonin permeated versus time) with the
slope (permeation rate, mg h1) equal to PACd where P is the permeability
coefﬁcient, A the surface area of the PCL membrane in cm2, and Cd the value of
the saturation concentration of the drug in HPbCD/PBS solution.For all drug compounds studied the tL, which may be evaluated
in similar manner via this method, was clearly observed and was
found in contrast to be 2.5 h (i.e. the time where the curve
ﬂatlined), after which time the J values became constant. Hence,
there is a difference in the measured tL value of 1 h between the
two plots although the prescribed method for determining tL is
the steady-state time intercept method as embodied in Fig. 1.
Knowledge of tL is useful in determining some initial formulation
parameters (for example drug load, device size, and shape) when
investigating a matrix delivery system as it is known to vary from
drug to drug as well as between different systems [23].
Fig. 3 is a summary of the drug permeation rates, as calculated
from the slope of the total mg versus time plot, over the entire
permeation proﬁle plot (due to the variation in tL between different
drug compounds resetting to zero was not performed). These data
were obtained from two (for dexamethasone valerate and proges-
terone), four (for abamectin, amoxicillin, dexamethasone, ketopro-
fen, melatonin, and oestradiol benzoate), and six (for oestradiol
17b) duplicate tests. The linearity of the plots as indicated by R2
values of 0.980 or greater for most compounds indicated good
reproducibility in the data measured. However, in contrast, the
plot obtained for amoxicillin gave an R2 value of only 0.762. This
inferred that this particular drug was unstable under the conditions
of measurement employed (i.e. 37 1C and 48 h) as over this period,
a yellow colouration developed in the initially colourless solution
indicating a possible degradation of the amoxicillin [20].
In general, most drugs studied apart from ketoprofen displayed
low to zero permeation rates through the membranes. Progesterone
and melatonin displayed similar, albeit low permeation rates.
Calculations of the permeability coefﬁcient (P) for the drugs gave
values ranging from 1.04105 to 4.94109 cm s1with most
values below 1107 cm s1 including progesterone (see Table 4).
Table 4
Permeability coefﬁcients (P) of the eight selected drugs of interest and progester-
one compared against the solubility of each drug (Cd) in aqueous solution and in
HPbCD/PBS solution.
Drug Permeability
coefﬁcient (P)a
(cm s1)
Cd aqueous
b
(lg mL1)
Cd HPbCD/PBS
(lg mL1)
Abamectin 5.73106 3 8
Amoxicillin 4.94109 4385 12699
Dexamethasone 1.71107 108 3036
Dexamethasone valerate 2.89106 12 282
Ketoprofen 1.02105 284 427
Melatonin 1.12106 3273 6615
Oestradiol 17-b 8.08106 7 1997
Oestradiol benzoate 1.04105 1 142
Progesterone 2.50106 16 3711
a Permeability coefﬁcient (P) calculated by dividing the ﬁnal permeation rate
(mg s1) by the product of the PCL membrane’s area and the drug’s solubility in
HPbCD/PBS, i.e. ‘‘Cd HPbCD/PBS’’ (mg mL1).
b ‘‘Cd aqueous’’ is deﬁned as the solubility of the drug in aqueous solution.
Table 5
Least squares regression correlations (R2) of the drug physicochemical properties
M, pKa, log Kow, Cd (in water and HPbCD/PBS solution), permeation rate, and
permeability coefﬁcient (P) for the bioactive compounds studied.
pKa Log Kow Cd
(aqueous)
Cd (HPbCD/
PBS)
Rate P
M 0.0319 0.2845 0.0346 0.0999 0.2038 0.0092
pKa 1.0
a 0.3901 0.2587 0.5486 0.2199 0.0412
Log Kow –
b 1.0 0.5284 0.6924 0.0294 0.3839
Cd (aqueous) – – 1.0 0.8223 0.0123 0.2887
Cd (HPbCD/
PBS)
– – – 1.0 0.0073 0.2737
Rate – – – – 1.0 0.2030
P – – – – – 1.0
a Correlations of ‘‘1.0’’ are expected when you are calculating the coefﬁcient of
plots of parameters against themselves.
b ‘–’ Represents mirrored results so not repeated. If repeated this value would
be 0.3901.
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insert containing progesterone has been carried out and shown to
be as clinically effective as the currently available commercial
products on the market [14], it is appropriate to compare the
permeation results of progesterone through PCL with those of the
other drug compounds investigated in this study. The results in
Fig. 3 are interesting in that only melatonin and ketoprofen have
similar or better permeation rates when compared to progester-
one. The oestradiol drugs display a rate approximately one ﬁfth
that of progesterone, and both the dexamethasone candidates less
still (approximately one tenth) with abamectin and amoxicillin
indicating almost zero permeation. According to these results
only melatonin and ketoprofen ‘‘appear’’ to display permeation
rates that would make them suitable for incorporation into a PCL
matrix. This assessment however ignores any consideration of the
drug dosage requirements as well as a number of other pharma-
cokinetic or physicochemical parameters important in controlled
drug delivery. To assess whether or not potential applications
exist with the drug compounds tested the factors that inﬂuence
the drug/PCL permeation rate need to be considered.
The nine drug compounds investigated displayed a range of
molar mass (M), solubilities (as dictated by log Kow used to
measure the hydrophilicity/hydrophobicity factors in a molecule
that inﬂuence partitioning between a polar and non-polar sol-
vent) and saturation concentrations (Cd). Each of these para-
meters is known to inﬂuence the diffusion coefﬁcient and hence
ﬁnal permeation rate. The combination of a low M, high Cd, and
low log Kow for ketoprofen favoured diffusion through the sol-
vated regions of the polymer resulting in the high ﬁnal permea-
tion rate observed. Conversely the large M and log Kow of
abamectin along with its poor solubility in aqueous solution did
not favour regional diffusion through the PCL polymer. The ﬁnal
permeation rates do not relate to one, two, or three principal
factors but a combination of these factors favouring diffusion
through the solvated PCL polymer. Table 5 provides an assess-
ment of the least squares regression (R2) values of the physico-
chemical property parameters M, pKa, log Kow, Cd for water, and
HPbCD/PBS-based media, permeation rates, and permeability
coefﬁcients (P) versus each other in all the combinations noted
in the table. For instance, the R2 value for values of molecular
weight of candidate drugs used in this study versus the perme-
ability rates observed for the same drugs from PCL is 0.2038.
Some physicochemical parameters which are closely related were
seen to have good correlations such as the solubilities of the drug
in water and HPbCD/PBS media (i.e. Cd water and Cd HPbCD/PBS)as well as the log Kow when correlated to M and pKa but no
particularly strong correlations were seen for permeation rate or
permeability coefﬁcients correlated versus the physicochemical
properties (the best of these were 0.22 with pKa versus perme-
ability rate and 0.38 with log Kow versus permeability rate).
Earlier reported studies on the permeation of three oestrogens
(oestrone, oestradiol, oestriol) and dexamethasone across cellu-
lose acetate [24] showed that an increase in permeation was
correlated with increased temperature and log Kow, decreased
polarity and fewer attached hydroxyl groups. That research
implied that diffusion (for these steroids) occurred through
aqueous channels within the membrane and that obstruction
and polar interactions were a limitation to permeation.
Cyclodextrins are known permeation enhancers [25–27] for
poorly soluble drug compounds through biological and synthetic
membranes. It has been stated that cyclodextrins enhance per-
meation by carrying the drug through the aqueous diffusion layer
(a barrier to diffusion) from the bulk solution towards the
membrane surface. At the membrane surface the drug partitions
from the drug-cyclodextrin complex into the membrane (often
lipophilic as is the case for PCL). This illustrates the importance of
the solubility and log Kow parameters in determining the permea-
tion rate. The interaction between the drug and cyclodextrin
(assuming equilibrium) counteracts the partition process but
remains necessary in order to obtain a signiﬁcant chemical
potential gradient for diffusion to occur. This is but one interac-
tion that describes why no particular parameter (M, pKa, log Kow,
Cd (water and HPbCD)) is dominant in determining drug permea-
tion through PCL.3.1.1. Studies of drug release from drug/PCL devices by Hanson
dissolution studies
A summary of the melt extruded PCL/drug samples manufac-
tured for this study are summarised in Table 6. It was acknowl-
edged that the introduction of different drug compounds into the
polymer could potentially alter the nature of drug/polymer
interactions as well as the pharmaceutical properties of the ﬁnal
drug/PCL device. With the aim of making physically uniform melt
extruded materials, the manufacturing methodology was kept as
consistent as possible although proving this using a technique like
scanning electron microscopy (SEM) was difﬁcult because it was
challenging to distinguish on the basis of EDX spot analyses the
difference between PCL or drug-originating features such as
crystals. This is because both the PCL and the drugs tested only
Table 6
The number of individual devices (N) manufactured from the drug load per cent
(%) w/w chipped material with the average surface area (mm2) of each drug device
analysed.
Drug N Drug load (%) w/w Area (mm2)
Abamectin 3 10.5 157574
Amoxicillin 3 10.3 1556726
Dexamethasone 3 10.1 1603715
Dexamethasone valerate 3 10.1 1489732
Ketoprofen 3 10.3 1611732
Melatonin 3 10.3 1669710
Oestradiol 17-b 8 10.5 1523758
Oestradiol benzoate 8 10.2 1535749
Progesterone 63a 10.0 1602750
a Includes all of the PCL devices manufactured for method development and
validation of the standard Hanson dissolution test method which explains the
large number produced.
Fig. 4. Hanson dissolution data showing the average release rates (mg cm2 h0.5)
in 15% aqueous alcohol determined from the slope of the release versus the
square-root-of-time plot for the nine drug/PCL devices investigated. Error bars
represent variations for 3 duplicates of each compound tested.
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would not provide characteristic signals for each component.
Hence the different drug/polymer interactions that could result
over the range of compounds melt extruded with PCL must still be
considered as a factor when attempting to compare the ﬁnal
release rates of the nine drugs of interest when measured by
Hanson dissolution. The other factor to be borne in mind when
comparing the Hanson dissolution results with the permeation
studies is that a different release medium was used for this
purpose, namely a 15% v/v SDA/water solution employed to
simulate the bovine vaginal membrane which will behave like a
typical amphiphilic biological membrane and have both hydro-
phobic and hydrophilic characteristics.3.2. Hanson dissolution test
The validation of the standard Hanson dissolution test method
showed that the particular test parameters adopted for the
progesterone/PCL devices were appropriate even though, proges-
terone does have some signiﬁcant physicochemical differences
from the other eight selected drug candidates studied, in parti-
cular, the absence of a pKa value. After developing an appropriate
drug release test using the progesterone/PCL devices (by investi-
gating the inﬂuence of a number of different method parameters
with this system) the release rates of the eight drugs of interest
(plus progesterone for comparison reasons) were assessed. A
relationship is known to exist between dissolution and bioavail-
ability [28] but given the number of contributing factors able to
inﬂuence the dissolution process it is unlikely that a single test
method can be applied to all drug compounds. The ultimate aim
of an in vitro dissolution assessment is to provide information on
the drugs’ absorption potential in vivo via determination of the
kinetics of the dissolution process (the rate limiting step in
bioavailability). Most models focus on the in vitro dissolution
data to assess bioavailability ignoring the inﬂuence of in vivo
dissolution following administration. This limitation arises
because of the difﬁculty in assessing in vivo dissolution [28]. As
a result the release rates for the nine drugs investigated (Fig. 4) do
not indicate whether or not, following dissolution, they are
actually bioavailable only that on administration they become
potentially bioavailable. The other important factor to note is that
this will apply only to dissolution rate limited drugs and not to
those which are permeation-limited for which increased dissolu-
tion will not lead to increased availability by absorption through
membranes. Ranking different drug release rates according to a
single Hanson dissolution test procedure thus gave a simplistic
but useful comparison that was used to assess the viability ofdifferent drugs that had not been previously considered for
incorporation into a PCL matrix delivery device.
Fig. 4 provides a summary of the average release rates of the
nine drugs of interest when measured using the standard Hanson
dissolution test method. It is clear from the ﬁgure that the drugs,
dexamethasone, dexamethasone valerate, ketoprofen, and mela-
tonin exhibited release rates exceeding 100 mg cm2 h0.5 which
compared favourably with release behaviours exhibited by an
existing commercial intravaginal device that incorporates proges-
terone [14]. The drugs with release rates approximately one tenth
this limit or less (viz., abamectin, amoxicillin, oestradiol 17-b,
and oestradiol benzoate) would require the methodology by
which they are incorporated into the PCL matrix (i.e. drug load,
co-polymer addition or different polymer for co-extruding,
additional excipients, etc.) [2,29–32] to be modiﬁed if they ever
were to be part of a viable controlled release PCL matrix delivery
device. There are clearly limitations with using these drugs with
the present scenario of testing. Based on the release rates
obtained from the Hanson dissolution experiments alone, dex-
amethasone, dexamethasone valerate, ketoprofen, and melatonin,
appear to show the greatest potential for adaptation into a matrix
delivery device, with the results observed for progesterone
reafﬁrming its expected suitability as a candidate when based
on past experiences from other researchers. Abamectin and
amoxicillin, on the other hand, did not exhibit high release rates
and furthermore had earlier showed very poor permeability
which renders them as unfavourable candidates for PCL matrix
devices given the present methodologies used in this study. In the
case of amoxicillin this had been due to the possibility that it was
unstable under the experimental conditions used.
From the drug permeation rate studies shown earlier, ketoprofen,
melatonin, oestradiol 17-b, and oestradiol benzoate, gave the
appearance of being suitable for potential adaptation into a PCL
delivery device. However, the poor Hanson dissolution release rates
of both oestradiol-based drug species (17-b and benzoate) precludes
them as possible device adaptation candidates. Possibly better
device manufacture or a different mode of Hanson dissolution
methodology may be needed to explore the utility of PCL/oestradiol
drug matrices. Dexamethasone and dexamethasone valerate though
giving visibly poor permeation rate results gave more encouraging
release rates via Hanson dissolution and this contrasting behaviour
may highlight a possible limitation to drug delivery for these drug
species via a PCL matrix device if permeation, alone, was to be relied
upon as a major part of the drug delivery.
Finally in seeking to understand the release results provided by
the Hanson dissolution study, it is of value to calculate some R2
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versus physicochemical properties of the drugs used. It was also of
interest to determine if any correlations could be seen between
the sets of permeation rate and Hanson dissolution rate data. It is
known that a variety of factors can inﬂuence dissolution rate
in vitro with six main classes identiﬁed according to the literature
[33,34]. These relate to method and instrumental variations, drug
dosage and formulation, other miscellaneous factors and also
physicochemical properties of the drugs themselves. These were
expected to have an impact on the release properties of the drugs
test [28,35] but when least squares regression correlations of the
physicochemical properties (M, pKa, log Kow, and solubility of the
drugs in aqueous solution) against release rate for the nine drugs
analysed were calculated, these were not strong (0.1621, 0.1039,
0.0407, and 0.0380, respectively). This suggests that no one factor
is responsible for controlling the dissolution process but rather a
number of factors operating simultaneously to inﬂuence the ﬁnal
release rate observed. Secondly, when the permeation rate data
from earlier are plotted against the release rate data (determined
using the standard Hanson dissolution test method), for the nine
selected drug candidates, an R2 correlation of 0.5675 is obtained.
This value suggests that a moderate relationship exists between
permeation rate and release rate for the nine selected drugs.
Hence one can say that the processes involved in drug permeation
through a PCL membrane and the dissolution (release) of a drug
out of a PCL matrix device are diffusion controlled and/or inﬂu-
enced by a combination of the drug physicochemical properties.4. Discussion and conclusions
The combination of side-by-side diffusion cell experiments
and Hanson dissolution studies of novel drug combinations with
PCL has led to some useful data on the utility of these combina-
tions as drug delivery vehicles. Before discussing these it is
important to reiterate that different scenarios are being tested
in each of these experiments, i.e. permeation versus Hanson
dissolution. One experiment involves permeation of drug from a
saturated solution containing cyclodextrin through a thin PCL
membrane into an aqueous receptor ﬂuid of similar composition
but without any dissolved drug. The other experiment is a Hanson
dissolution study of release directly from a PCL matrix containing
the drug immersed into an aqueous alcoholic mixture, the release
medium. Permeability studies were carried out to shed light on
which of the relatively little tested drugs would perform the best
if combined into a PCL matrix. With the permeability data
obtained to get some initial insights, Hanson dissolution studies
were then performed in aqueous alcohol media to ﬁnally correlate
these release rates with those from the permeability experiments.
In summary, side-by-side diffusion cell experiments, for the
nine drugs studied permeating through a PCL membrane, gave
permeation rates ranging from 0 to 122 mg h1. Apart from
ketoprofen which demonstrated an exceptionally high permea-
tion rate, other drug candidates displayed relatively lower per-
meation rates with permeability rate following the trend
progesterone4melatonin4oestradiol (both)4dexamethasones
(both)4abamectin and amoxicillin. Least squares regression
(R2) values obtained by plotting the measured permeation rates
against the drug physicochemical properties of M, pKa, log Kow,
and solubility (in water and HPbCD/PBS solutions) showed no
especially strong correlations, therefore, suggesting that a variety
of drug physicochemical factors acting together could inﬂuence
permeation.
Hanson Dissolution release rates for the PCL-melt-extruded
drug matrices tested in 15% aqueous alcohol release media gave
numerically higher values than the permeability experiments,ranging from 0 to 556 mg cm2 h0.5. In attempting to compare
the two (permeability versus Hanson dissolution) values against
each other, the higher values from the Hanson dissolution
experiment can be understood in terms of the units used for each
experiment. Numerically the Hanson dissolution value unit
contains a surface area term mg cm2 h0.5 while permeability
rate values only have an amount per unit time unit (mg h1).
Multiplying the Hanson dissolution value through by the drug
device surface area (Table 6) to get an approximate comparison
with the permeability data (in terms of mg h0.5 instead
of mg h1) leads to an even larger number so reafﬁrming the
larger numerical values obtained for this particular experiment.
The other reason for the observed higher numbers in Hanson
dissolution must be attributed to the 15% v/v SDA solvent chosen
as the release medium and mimic for an amphiphilic membrane.
Hence in contrast to the permeation results, under the testing
conditions used, the Hanson dissolution release rate ranking
followed the trend: ketoprofen4progesterone4dexamethasone
valerate4melatonin4dexamethasone4abamectin (and) amox-
icillin4oestradiols (both). One drug, amoxicillin, performed
poorly in both permeability and Hanson dissolution studies due
possibly to decomposition issues under the conditions employed
leading to the lack of UV detection. The R2 values obtained when
either the permeability rate or average Hanson dissolution release
rate of all the drugs tested were plotted against the drugs’
physicochemical properties showed numbers considerably o1
indicating that no strong correlations existed which meant that
no one drug physiological property was responsible for trends
observed. However, a moderate correlation (R2 of 0.5675)
obtained when Hanson dissolution release rate data were plotted
against the permeation rate data suggested that release rate and
permeation rate processes are partly inﬂuenced by the rate of
drug diffusion through the PCL but that drug release involves an
additional dissolution process to take place into the release
medium (inﬂuenced by drug solubility) before diffusion of the
drug may proceed out of the PCL.
In conclusion, based on both sets of data obtained in this
study, it is evident that the oestradiol-based drugs, abamectin
and amoxicillin are generally unsuitable as candidates for drug
delivery via PCL under the conditions used. Ketoprofen, on the
other hand, was found to be a highly favourable candidate for
further development of applications involving melt extrusion
with PCL with dexamethasone valerate, dexamethasone and
melatonin also being favourable but to a lesser extent.Acknowledgements
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